-
公开(公告)号：US20090036364A1
公开(公告)日：2009-02-05
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20080312157A1
公开(公告)日：2008-12-18
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08263545B2
公开(公告)日：2012-09-11
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
4.发明授权公开(公告)号：US08497240B2
公开(公告)日：2013-07-30
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08404637B2
公开(公告)日：2013-03-26
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
6.发明申请公开(公告)号：US20110136737A1
公开(公告)日：2011-06-09
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/22 , C07K14/645 , C07K14/605 , A61K38/26 , A61P3/10 , A61P9/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08895498B2
公开(公告)日：2014-11-25
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/00 , A61P3/10 , C07K7/06 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20130137631A1
公开(公告)日：2013-05-30
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： C07K14/575 , C07K7/06
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
公开(公告)号：US20100029554A1
公开(公告)日：2010-02-04
申请号：US12301199
申请日：2007-05-25
申请人： Soumitra S. Ghosh , Diana Y. Lewis , Samuel Janssen , Ved Srivastava , Que Liu , Carolyn M. Jodka , Christopher J. Soares , Qing Lin
发明人： Soumitra S. Ghosh , Diana Y. Lewis , Samuel Janssen , Ved Srivastava , Que Liu , Carolyn M. Jodka , Christopher J. Soares , Qing Lin
CPC分类号： C07K14/605 , A61K38/00 , C07K14/57563
摘要： Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects.
摘要翻译： 本文提供使用GLP-1分子或其激动剂及其类似物，以及使用毒蜥外泌肽分子或其激动剂及其类似物，包括其衍生物和活性片段来预防或治疗充血性心力衰竭。 还公开了用于本文所述方法的药物组合物。 还提供了用于治疗和/或预防糖尿病，高血糖症，胰岛素抵抗和肥胖以及减少食物摄取和抑制受试者食欲的组合物和方法。
-
公开(公告)号：US20100009907A1
公开(公告)日：2010-01-14
申请号：US12302456
申请日：2007-07-06
IPC分类号： A61P7/12 , C07K7/06 , C07K7/08 , C07K14/00 , A61P3/00 , C07K14/76 , C07K16/00 , C07H21/04 , A61K38/08 , A61K38/10 , A61K38/16 , A61P1/00 , A61P11/00
CPC分类号： C07K14/605 , C07K2319/31
摘要： The present invention relates to non-mammalian Glucagon-like peptides (nmGLP-1), analogs thereof, related nucleic acids, and processes production of such peptides. The nmGLP-1 peptides and analogs thereof of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent obesity, reducing body weight, controlling glycemia, controlling or reducing appetite, and reducing food intake.
摘要翻译： 本发明涉及非哺乳动物胰高血糖素样肽（nmGLP-1），其类似物，相关核酸，并且处理这些肽的产生。 本发明的nmGLP-1肽及其类似物包括一个或多个氨基酸序列修饰。 此外，公开了治疗和预防肥胖，减轻体重，控制血糖，控制或减少食欲和减少食物摄入的方法和组合物。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.084 秒)
